Thapa, Bicky
Kato, Shumei
Nishizaki, Daisuke
Miyashita, Hirotaka
Lee, Suzanna
Nesline, Mary K.
Previs, Rebecca A.
Conroy, Jeffery M.
DePietro, Paul
Pabla, Sarabjot
Kurzrock, Razelle
Article History
Received: 10 November 2023
Accepted: 20 March 2024
First Online: 25 March 2024
Declarations
:
: N/A.
: N/A.
: Bicky Thapa, Daisuke Nishizaki, Hirotaka Miyashita, and Suzanna Lee declare no conflict of interest. Shumei Kato serves as a consultant for Medpace, Foundation Medicine, NeoGenomics, and CureMatch. He receives speaker’s fee from Chugai, Roche/Genentech and Bayer, and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta, OmniSeq, Personalis, and Function Oncology. Mary K. Nesline and Rebecca A. Previs are employees of Labcorp and declare stock ownership in Labcorp. Sarabjot Pabla, Jeffery M. Conroy, and Paul DePietro are employees of Omniseq and declare stock ownership in Labcorp. Razelle Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, and X-Biotech; has an equity interest in CureMatch Inc. and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch.